CoreBiome Announces Leading Microbiome Researcher Rob Knight as Scientific Advisor
25 4월 2019 - 9:00PM
Business Wire
CoreBiome, a microbiome discovery services provider and
wholly-owned subsidiary of OraSure Technologies, Inc. (NASDAQ:
OSUR), announced today that Rob Knight, Professor and Director of
the Center for Microbiome Innovation at the University of
California San Diego, has joined its scientific advisory board.
As an investigator on the National Institutes of Health Human
Microbiome Project and a co-founder of the American Gut Project,
Dr. Knight is one of the world’s leading microbiome researchers.
Dr. Knight’s research tools have played a major role in the
development of microbiome science. His research has been published
in over 500 peer-reviewed research articles that collectively have
been cited over 150,000 times.
“We are thrilled to have Rob Knight joining CoreBiome as a
scientific advisor. Rob has pioneered many of the foundational
tools that microbiome science is built upon,” says CoreBiome CEO
Dan Knights. “Rob has been a key investigator on many breakthrough
clinical discoveries, and has a great sense of where the current
and future needs are for microbiome scientists.”
Dr. Knight’s unique position as an expert in both computational
and molecular biology will allow him to advise CoreBiome on
opportunities for innovation at the bench and in the cloud. Ongoing
tool development at CoreBiome and its sister company DNA Genotek
will help customers gain insight into the function activity and
byproducts of the microbiome.
Dr. Knight said of his appointment, “I believe it’s extremely
important to the whole microbiome field to give all investigators
access to high-resolution microbiome data and data mining at a
massive scale. I am very excited to be a part of ongoing efforts to
make that happen.”
With the launch of BoosterShot™, CoreBiome has led the field in
making high-resolution metagenomic DNA sequencing accessible to
population-scale studies. In 2019, CoreBiome was acquired by
OraSure Technologies, which also owns DNA Genotek, a leading
provider of sampling and stabilization kits, bringing together an
end-to-end solution for robust microbiome discovery – from sample
collection to sequencing to custom data mining. CoreBiome also
provides ultra-high-throughput deep shotgun metagenomics and strain
discovery.
“Having Rob as an advisor will support CoreBiome’s mission, to
accelerate discovery for the whole field by giving our customers
access to big data and good data at the same time,” said CoreBiome
Data Science Manager Tonya Ward. “It’s not just about generating a
ton of data. The data have to be high quality, and you also have to
know what to do with the data once you get it. We help customers do
all of the above.”
About CoreBiome:CoreBiome is a microbiome genomics
company focused on accelerating microbiome discovery for customers
in the pharmaceutical, agriculture, and research communities, to
unleash the translational potential of the microbiome. The
company’s proprietary BenchMark™, BoosterShot™, and Core Analysis™
platforms provide fast and information-rich characterizations of
microbial diversity and function, paired with machine learning and
expert analytics. CoreBiome is a wholly-owned subsidiary of OraSure
Technologies, Inc., which also owns DNA Genotek, a leading provider
of sampling and stabilization kits. For more information about
CoreBiome, visit http://www.corebiome.com.
About OraSure Technologies:OraSure Technologies is a
leader in the development, manufacture and distribution of
point-of-care diagnostic and collection devices and other
technologies designed to detect or diagnose critical medical
conditions. Its first-to-market, innovative products include rapid
tests for the detection of antibodies to HIV and HCV on the
OraQuick® platform, oral fluid sample collection, stabilization and
preparation products for molecular diagnostic applications, and
oral fluid laboratory tests for detecting various drugs of abuse.
OraSure’s portfolio of products is sold globally to various
clinical laboratories, hospitals, clinics, community-based
organizations and other public health organizations, research and
academic institutions, distributors, government agencies,
physicians’ offices, commercial and industrial entities and
consumers. The Company’s products enable healthcare providers to
deliver critical information to patients, empowering them to make
decisions to improve and protect their health.
Important Information
This press release contains certain forward-looking statements.
Forward-looking statements are not guarantees of future performance
or results. Known and unknown factors that could cause actual
performance or results to be materially different from those
expressed or implied in these statements include, but are not
limited to: ability to successfully manage and integrate the
acquisitions in a manner that complements or leverages our existing
business, or otherwise expands or enhances our portfolio of
products and our end-to-end service offerings, and the diversion of
management's attention from our ongoing business and regular
business responsibilities to effect such integration; failure to
realize the expected economic benefits of the acquisitions (and
increased returns for our stockholders), including that the
anticipated synergies, revenue enhancement strategies and other
benefits from the acquisitions may not be fully realized or may
take longer to realize than expected or that our actual integration
costs may exceed our estimates; ability to market and sell
products, whether through our internal, direct sales force or third
parties; ability to manufacture products in accordance with
applicable specifications, performance standards and quality
requirements; ability to obtain, and timing and cost of obtaining,
necessary regulatory approvals for new products or new indications
or applications for existing products; ability to comply with
applicable regulatory requirements; ability to effectively resolve
warning letters, audit observations and other findings or comments
from the U.S. Food and Drug Administration (“FDA”) or
other regulators; changes in relationships, including disputes or
disagreements, with strategic partners or other parties and
reliance on strategic partners for the performance of critical
activities under collaborative arrangements; ability to meet
increased demand for the Company’s products; impact of significant
customer concentration in the genomics business; impact of
increased reliance on U.S. government contracts; failure of
distributors or other customers to meet purchase forecasts,
historic purchase levels or minimum purchase requirements for our
products; impact of replacing distributors; inventory levels at
distributors and other customers; ability of the Company to achieve
its financial and strategic objectives and continue to increase its
revenues, including the ability to expand international sales;
ability to identify, complete, integrate and realize the full
benefits of future acquisitions; impact of competitors, competing
products and technology changes; impact of negative economic
conditions; reduction or deferral of public or other funding
available to customers; competition from new or better technology
or lower cost products; ability to develop, commercialize and
market new products; market acceptance of oral fluid or urine
testing, collection or other products; market acceptance and uptake
of microbiome informatics, microbial genetics technology and
related analytics services; changes in market acceptance of
products based on product performance or other factors, including
changes in testing guidelines, algorithms or other recommendations
by the Centers for Disease Control and Prevention (“CDC”) or
other agencies; ability to fund research and development and other
products and operations; ability to obtain and maintain new or
existing product distribution channels; reliance on sole supply
sources for critical products and components; availability of
related products produced by third parties or products required for
use of our products; ability to maintain sustained profitability;
ability to utilize net operating loss carry forwards or other
deferred tax assets; volatility of the Company’s stock price;
uncertainty relating to patent protection and potential patent
infringement claims; uncertainty and costs of litigation relating
to patents and other intellectual property; availability of
licenses to patents or other technology; ability to enter into
international manufacturing agreements; obstacles to international
marketing and manufacturing of products; ability to sell products
internationally, including the impact of changes in international
funding sources and testing algorithms; adverse movements in
foreign currency exchange rates; loss or impairment of sources of
capital; ability to meet financial covenants in credit agreements;
ability to attract and retain qualified personnel; exposure to
product liability and other types of litigation; changes in
international, federal or state laws and regulations; customer
consolidations and inventory practices; equipment failures and
ability to obtain needed raw materials and components; the impact
of terrorist attacks and civil unrest; and general political,
business and economic conditions. These and other factors that
could affect our results are discussed more fully in the
Company’s Securities and Exchange Commission (“SEC”)
filings, including our registration statements, Annual Report on
Form 10-K for the year ended December 31, 2017, Quarterly
Reports on Form 10-Q, and other filings with the SEC. Although
forward-looking statements help to provide information about future
prospects, readers should keep in mind that forward-looking
statements may not be reliable. The forward-looking statements are
made as of the date of this press release and OraSure
Technologies undertakes no duty to update these
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190425005077/en/
CoreBiome Media ContactEve
Grabauegrabau@corebiome.com
OraSure Media ContactJeanne Mellmedia@orasure.com
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024